Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hypersensitivity Reactions: Immune-Complex Reactions

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.

JCI insight·2025

Same author

Characteristics of youth utilizing pediatric dermatology: A cross-sectional PEDSnet study.

Journal of the American Academy of Dermatology·2025

Same author

Development and Validation of a Scale to Assess Epidermolysis Bullosa Simplex Severity.

JAMA dermatology·2025

Same author

Dupilumab Reduces Pruritus in Twins With Sjögren-Larsson Syndrome.

Pediatric dermatology·2025

Same author

Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.

Dermatology and therapy·2025

Same author

Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry.

American journal of clinical dermatology·2025

Same journal

<i>Letter:</i> Anogenital Dermatitis Rarely Occurs in Isolation: Disease Distribution and Delays in Patch Testing.

Dermatitis : contact, atopic, occupational, drug·2026

Same journal

Practical Techniques: Photopatch Testing.

Dermatitis : contact, atopic, occupational, drug·2026

Same journal

Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi Consensus.

Dermatitis : contact, atopic, occupational, drug·2026

Same journal

Digital Image Superimposition for Identifying Delayed Patch Test Reactions: A Clinical Pearl.

Dermatitis : contact, atopic, occupational, drug·2026

Same journal

Analysis of Sulfite Concentrations in Common Beverages Consumed in the United States.

Dermatitis : contact, atopic, occupational, drug·2026

Same journal

<i>Letter:</i> Nickel Sensitization After Patent Foramen Ovale Closure.

Dermatitis : contact, atopic, occupational, drug·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 29, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled Analysis.

Amy S Paller^1,2, Marjolein de Bruin-Weller³, Eric L Simpson⁴

¹From the, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Dermatitis : Contact, Atopic, Occupational, Drug

|October 30, 2025

Summary

This summary is machine-generated.

Dupilumab for moderate-to-severe atopic dermatitis (AD) showed a slight increase in facial rash treatment-emergent adverse events (TEAEs) compared to placebo. Most facial rash cases were mild-to-moderate and resolved without treatment discontinuation.

Keywords:

atopic dermatitis dupilumab facial rash

More Related Videos

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

Related Experiment Videos

Last Updated: Jun 29, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

Area of Science:

Dermatology
Clinical Pharmacology

Background:

Dupilumab, approved in 2017 for moderate-to-severe atopic dermatitis (AD), has been associated with reports of facial rash in post-marketing literature.
Understanding the incidence and characteristics of facial rash is crucial for patient management.

Purpose of the Study:

To quantify the incidence of facial rash treatment-emergent adverse events (TEAEs) in patients with moderate-to-severe AD participating in dupilumab clinical trials.
To analyze specific facial rash events using MedDRA Lowest Level Terms (LLTs).

Main Methods:

Pooled data from 14 randomized, placebo-controlled clinical trials involving pediatric and adult patients with moderate-to-severe AD.
Systematic search for facial rash TEAEs during the study treatment period, categorized by MedDRA LLTs.

Main Results:

The study included 1349 placebo-treated and 2615 dupilumab-treated patients.
Facial rash incidence was low but numerically higher in the dupilumab group (1.0%) compared to placebo (0.7%).
Specific LLTs like erythema facial, redness facial, and rash on face showed slightly higher rates with dupilumab. Most events were mild-to-moderate and resolved.

Conclusions:

Analysis of MedDRA LLTs in dupilumab trials for moderate-to-severe AD indicates a small increase in facial rash incidence compared to placebo.
The observed facial rashes were predominantly mild-to-moderate and did not necessitate treatment discontinuation, suggesting a manageable safety profile regarding this adverse event.